Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q3 2024 Earnings Presentation
7 slides from Avita Medical's earnings presentation, Nov 8, 2024
Slide 1: Q3 2024 Earnings Presentation
Q3 2024 Earnings Presentation November 7, 2024
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this pre
Slide 3: Accelerating RECELL GO Account Conversions
Accelerating RECELL GO Account Conversions Multiple devices Enhanced features Effectively maximize operating reduce training burden treats large wounds room efficiency Burn injury between Burn injury between Burn injury between 10% - 20% TBSA 20% - 30% TBSA 50% - 60% TBSA P3
Slide 4: RECELL at the Core of a Comprehensive Portfolio
BUILDING A BROAD-BASED WOUND CARE COMPANY RECELL at the Core of a Comprehensive Portfolio Continuum Of Burn And Full-thickness Skin Defect Wound Care Flagship Device Wound Depth Wound Bed Wound Bed Dermal Dressings Wound Scar Assessment Preparation / Hemostasis Replacements / Epidermal Reduction / A
Slide 5: Product Compatibility for Wound Care
Product Compatibility for Wound Care CLINICAL PRESENTATION: FULL-THICKNESS WOUND Dressing optimized for protection and PermeaDerm by Stedical moisture management RECELL + meshed split- Robust closure using significantly less thickness skin graft skin compared to traditional grafting Generation of va
Slide 6: Quarterly Commercial Revenue
Quarterly Commercial Revenue STRONG COMMERCIAL GROWTH $25,000 $23,3001 Commercial Revenue (in thousands) $20,000 $19,482 $15,133 $15,000 $13,546 $14,097 $11,687 $11,069 $10,458 $10,000 $9,364 40% 42% 51% 50% 6% 29% 44% 65%1 Year-Over-Year Growth $5,000 $0 Ryan Zimmerman, BTIG (U.S.) Scott Power,
Slide 7: Slide 7